Move to topTop
August 16, 2018

TOKYO, JAPAN - August 16, 2018 - Terumo Corporation (TSE: 4543) today announced that David Perez will retire as president and chief executive officer (CEO) of Terumo BCT and that Antoinette Gawin, executive vice president, global commercial, will succeed him in both roles. Antoinette will become president on October 1, 2018 and will become CEO at the start of fiscal year 2019 on April 1, 2019. David also serves on the Terumo Corporation board of directors and will retire from this position at the end of his current term in June 2019.

David has served as an exemplary leader since he began his career with Terumo BCT, then called COBE BCT, in May 1999. He guided the company through multiple changes in ownership, including Gambro BCT and CaridianBCT and when the company joined Terumo Corporation in 2011. "David is an established leader in the global blood management and transfusion medicine industry and will leave behind an enduring legacy of leadership, impact and influence. Under his leadership, the company grew revenue almost sixfold, nearing $1 billion, and introduced multiple innovative products that have fundamentally changed and improved blood transfusion and cellular therapies. I would like to thank David for his contributions over many years and wish him every success in the future," said Shinjiro Sato, President and CEO of Terumo Corporation, Terumo BCT's parent company.

David Perez said: "It has been an honor and a privilege to lead Terumo BCT and to serve on Terumos Board of Directors. I have a deep emotional connection to the company, to our associates and customers, and to the patients we ultimately serve. When I retire, I will have been leading the company for almost 20 years and I am truly thankful for the incredible experiences that have shaped my life and will forever be part of who I am. I have complete confidence in Antoinette and her ability to build on our success and take the company to the next level by diversifying and expanding into growth areas."

Antoinette Gawin joined Terumo BCT in 2016 and has made significant contributions to the company through her strong focus on the voice of the customer. Prior to Terumo BCT, Antoinette served in leadership roles at Baxter overseeing global market access, commercial excellence and strategy. For 22 years prior to that, Antoinette worked in leadership positions at several GE subsidiaries, including GE Healthcare Technologies, GE Industrial and Power Systems, GE Information Services and GE Corporate. Living in Switzerland, London and the U.S. during her tenure at GE, she led global organizations and served in a broad range of influential roles, including chief marketing officer, chief executive officer and general manager.

Shinjiro Sato said: "I am very pleased to announce Antoinettes appointment after a very comprehensive selection process. David and I share the belief that Antoinette is the right person to lead Terumo BCT into the future. She is an outstanding leader with highly valuable experience and a strong track record of delivering growth and driving performance in healthcare."

Antoinette Gawin said: "I joined the Terumo BCT community to help shape healthcare. The solutions and clinical expertise we bring to the frontiers of medicine truly can unlock the potential of blood and cells to advance therapies. I am honored to be selected as Davids successor. Im looking forward to working with David and other leaders over the coming months to ensure a smooth handover and continue to develop plans for 2019 and beyond."

About Terumo BCT

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.